A group of nine pharmacy benefit managers (PBMs) announced Thursday that they will work with an industry group to boost the transparency of prescription drug pricing through the TrumpRx platform.
FOX Business exclusively learned that the Pharmaceutical Care Management Association (PCMA) and nine PBMs reached an agreement to showcase the cash price of prescriptions from TrumpRx within their benefit tools. The agreement aims to give patients better visibility into the cost of the medication and how they might save money on it.
“President Trump has made lowering prescription drug costs for Americans a priority, and this commitment is a step in the right direction,” CMS Administrator Dr. Mehmet Oz told FOX Business.
“By making negotiated drug prices available alongside cash prices on TrumpRx, this agreement will give patients greater visibility into how much they’re paying and help them find the best possible deal,” Oz explained. “That’s the kind of transparency we need to boost competition, drive down costs, and deliver better value for American patients.”
AMERICANS SAVE MORE THAN $700M ON PRESCRIPTION MEDICATIONS THROUGH TRUMPRX, WHITE HOUSE SAYS
The nine PBMs that are participating include CarelonRx, CVS Health, Express Scripts, Humana, MedImpact Healthcare Systems, Navitus Health Solutions, OptumRx, Prime Therapeutics and WellDyne.
Patients will be able to see TrumpRx prices if they’re enrolled in plans from those PBMs, including commercial, Medicare and Medicaid plans. The arrangement will cover all drugs that have a price on TrumpRx – either a presidential deal or a standard price.
PRESIDENT LAUNCHES TRUMPRX.GOV WEBSITE OFFERING AMERICANS DISCOUNTED PRESCRIPTION DRUG PRICES: ‘HISTORIC’
“Consumers and patients are better off when they have more options and a clear view of their costs,” said PCMA CEO David Marin. “If there are times when a product is cheapest on TrumpRx, patients should know that. This administration has embraced the use of real-time benefit tools to give patients more information, and we strongly embrace this technology.”
“This commitment will allow consumers to compare options and make better informed choices about costs and where they access prescription drugs. It’s a no-brainer for our industry and for American families,” Marin added.
TWO MAJOR DRUG COMPANIES ARE THE LATEST TO JOIN TRUMPRX
PCMA noted that the nine PBMs participating in this announcement are expected to provide price transparency on their benefit platforms starting on Jan. 1, 2027, though some may do so in other ways.
Some of the PBMs will use their Real Time Benefit Tools to display the cash price available on TrumpRx compared with the cost of the prescription through their plan’s coverage benefit at a network pharmacy, while others may pull in the TrumpRx pricing using other methods.
